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1. Introduction 
Plants have long been a source for traditional medicinal products. Indeed, greater than four 
billion people utilize plants to meet their primary health care [1-2]. There are >120 distinct 
drugs derived from plant sources representing >70% of the approved drugs in the past 20 
years [3, 4]. The manner to exploit the scale and cost advantages of agriculture while 
diversifying the product offerings made available by plants has been under intense 
investigation since the early 1980s. Traditional transgenic approaches were initially pursued, 
but the challenges associated with the transformation and regeneration of viable 
recombinant crops delayed the appearance of initial products of medicinal promise until 
1989 with the production of antibodies [5] and 1990 with the production of human serum 
albumin [6]. During this time, the concept of using plant virus genomes as expression 
vectors emerged. In early investigations, researchers recognized the natural capability of 
virus systems to change the translational priorities within infected cells such that virally 
encoded proteins were produced preferentially. This ability suggested that expression 
vectors could be constructed from viral nucleic acids to produce recombinant proteins 
throughout infected plants [7]. However, for this hypothesis to be tested, the genomes of 
viruses, starting with positive (+) strand RNA viruses, had to be cloned and characterized 
[8-10]. Soon after the first full-length “infectious” clones of a (+) strand RNA plant virus 
were constructed, and preceding traditional transgenic systems, the virus genome was 
converted into an expression vector [11]. Although limited with regards to in planta 
expression, this first vector revealed the promise of virus genomes to be efficient expression 
systems for plants. The advantages revealed in these early studies, continue to be present: 
cDNA “infectious clones” offer facile subcloning vehicles allowing rapid prototyping of 
genetic expression constructs, and recombinant protein expression levels that exceed that 
offered by transgenic systems. 
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The rapid replication cycle of the virus systems provided amplification of messenger RNA 
and the resulting proteins providing for a “burst” of recombinant expression that can 
provide impressive yields (reviewed in [12-15]). While these early vectors were useful in 
plant cell systems to produce recombinant protein products with potential market value 
[16], these early systems could not support large scale manufacturing nor did they exploit 
the advantages of agriculture to provide cost-effective products. This review will provide an 
overview of plant virus-based expression vectors, and provide select examples how virus 
expression systems have evolved to offer valuable tools for the production of medically 
important products [17] and support the study of plant structure and metabolic function 
(reviewed in [18]) in dicot- and monocotyledonous plants. The growing biomedical and 
agricultural markets have encouraged great creativity in the construction and testing of 
plant virus expression systems. 
2. Biomedical market for recombinant proteins 
As an example of the market drivers for plant-based expression vectors, the 
biopharmaceutical industry market will be briefly reviewed. Recombinant proteins, 
including monoclonal antibodies (mAbs), enzymes, hormones, cytokines and growth 
factors, and vaccine antigens, are the source for new medical therapies and the 
pharmaceutical market. The global pharmaceutical market continues to prove to be robust, 
>$850B in 2010, in spite of generic pressure and biosimilars appearance [19]. Recombinant 
protein drugs, known as biologics, expanded their market to $149B, including $48B in sales 
of the top selling monoclonal antibody (mAb) products treating cancer and other disorders 
[19, 20]. The global cancer therapeutic market is projected to continue growth at 12.6% 
compound annual growth rate through 2014 [21]. Monoclonal antibody immunotherapy has 
revolutionized the treatment of many diseases – most notably cancer where the 
nondestructive nature of mAb treatment synergizes with many existing therapies to result 
in improved efficacy. These molecules make up the most promising part of product 
portfolios for biopharmaceutical companies and this market is predicted to grow by 11-14% 
compounded annual growth rate (CAGR) in the next five years compared with the rather 
tepid growth of ~3% CAGR of small molecule drugs [22, 23]. Indeed, in the midst of an 
economic downturn (2008-2010), the growth in mAbs continues to occur with sales of 
therapeutic mAbs being $48B in 2010 compared with $40B in 2009 and $37B in 2008 [24]. 
Adding the $10B of sales for mAbs used for diagnosis and research reagents raises the total 
mAb market to $58B in 2010. The clinical development of immunotherapy has been revived 
after several breakthroughs that have led to the approval of drugs and treatment for cancer. 
Indeed, four of the top 10 mAbs in terms of sales, are used for cancer treatment [24]. New 
drug targets and associated drug interventions are under investigation that will provide 
therapeutic options for traditionally underserved populations. 
Recent successes and the growing market demand for more innovative biologic products to 
treat chronic patients has continued to fuel interest and investment to identify tools and 
strategies to accelerate discovery and product validation in immunotherapy fields. Further, 
clinical success is ultimately determined by established clinical endpoints indicative of 
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survival. However, these results often require monitoring for months to years after the 
therapy has been given to the patient. These timelines are not conducive to the iterative and 
experimental process that is cancer therapy. Therefore, surrogate markers are sought: more 
rapidly appearing measurements that correlate with longer-term clinical endpoints. These 
functions require access to relevant clinical samples from diseased and healthy patients as 
well as adapting laboratory assays to more clinical formats. Surrogate markers require 
specific assays used to demonstrate efficacy of immunologic therapies and, as noted above, 
will fuel extraordinary market growth in the coming decade. These assays are highly 
empirical and require well trained staff, highly controlled conditions and consistency in 
procedure to ensure trends in data can be validated as statistically significant. Diagnostic 
assays incorporating recombinant proteins or exploiting mAb for detecting and assessing 
medical conditions was $776M in 2010 and is expected to grow at a CAGR of 47% through 
2015 [25]. This growth in the use of biologics for immunotherapy and diagnostic products 
continues, in part, because of recent FDA approvals and physician implementation of 
several new immunology tools and immunotherapeutic products to diagnose and treat 
patients. 
3. Plant production of bio-pharmaceutical proteins 
Plants have steadily gained acceptance as alternative production systems for biologics. The 
recent United States Food and Drug Administration approval of Protalix Biotherapeutic’s 
Elelyso (taliglucerase alfa) [20] represents the successful realization of the goal for 
plant-produced human biologics, initiated soon after the formation of Agrigenetics in 1981. 
This product, produced in engineered carrot cells, benefits from the simpler culture 
conditions required by plant cells compared with Chinese hamster ovary (CHO), insect, or 
yeast systems. However, it still requires the capital intensive production methods, requiring 
multiplicative costs for increased scale [26]. Nevertheless, the approval of Elelyso, 
demonstrates that plants can be used to source biologics that meet the stringent demands for 
high quality in human products, at competitive scale and costs. Indeed, Protalix indicates 
that the lower production costs associated with carrot cell systems will allow pricing of 
Elelyso to be 75% of Cerezyme, the leading product in this market sector [20]. This approval 
strengthens the regulatory case for plant-based production systems that was established by 
the 2006 approval of a DowAgrosciences, LLC vaccine by the US Department of Agriculture 
for the prevention of Newcastle disease in chickens [27]. As with the Protalix product, this 
recombinant vaccine was derived from a transgenic plant cell culture system. 
Agriculture offers several advantages as a biologic production system. Plants allow 
capital-efficient design of upstream manufacturing capacity at various scales providing cost 
savings that cannot be easily matched by fermentation technologies. The market 
opportunities provided by follow-on biologics and the rising capital costs associated with 
production using traditional systems make plants particularly attractive. Considerable 
capital and time is required to construct the upstream facilities for cell culture production. 
The upstream facility must be linked with downstream capabilities supporting product 
purification and characterization. Although outdated, the published costs associated with 
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these facilities are $300–$500 million and require from four to five years to complete 
construction, validation, and to gain regulatory approval [28]. Agriculture-based production 
requires less specialized upstream facilities, typically controlled growth chambers, linked 
with similar downstream production capabilities. The use of plants therefore reduces capital 
expenditures and also provides for more flexible use of space and capital. 
The handling of plant biomass and its initial extraction requires unique biomanufacturing 
solutions [14]. Virus vector expression systems offer significant advantages at considerably 
reduced costs to current cell-based manufacturing systems, such as employed by Protalix 
and Dow AgroSciences, while avoiding concerns associated with stable plant transformation 
[29, 30]. Virus based expression systems have been extensively tested and shown safe and 
environmentally-friendly in both indoor and outdoor tests since 1991 [12] and multiple 
products completing early stage human clinical investigations [31, 32]. Additional 
advantages also exist compared with traditional cell-based fermentation approaches 
include: 1) speed and low cost of genetic manipulation; 2) rapid manufacturing cycles; 3) no 
mammalian pathogen contamination; 4) minimal endotoxin concentrations and 
5) economical production [12-15, 33, 34]. 
4. Types of plant virus-based expression vectors 
Many different types of plant viruses have been converted into vectors for the production of 
recombinant proteins or peptides (for complete review, see [12-15, 33, 34]). As different 
viruses have distinct biological limitations and gene expression potential, each vector 
system has its own unique opportunities. This review focuses on virus vectors that have 
been particularly useful to produce recombinant proteins for biomedical, therapeutic and  
 
Figure 1. The genomic structure of wild type Tobacco Mosaic tobamovirus RNA (a) and derivative 
independent (b) and minimal (c) expression vectors. Boxes represent the open reading frames on each 
RNA and are labeled with the the viral protein they encode. The 126K and 183K proteins are required 
for virus replication. The 30K gene is the virus movement protein required for cell-to-cell transport. The 
CP is the virus coat protein that is required for encapsidation and systemic movement. The green 
fluorescent protein (GFP) is used as a placeholder for a gene for protein overexpression in planta. 
Arrows indicate the position of subgenomic promoters used to express the downstream proteins. 
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research, use. Many groups have sought to categorize virus based expression systems. For this 
review, we will organize our thinking by using two categories: “independent-virus” or 
“minimal-virus”. Independent-virus vectors are replication competent vectors that can be 
principally inoculated to plants as virus particles or viral RNA, multiply in initially infected 
cells and exploit virus encoded cell to cell and systemic movement activities to infect the 
majority of the phloem sink tissue of a host. In contrast, minimal virus systems are replication 
competent systems that have be modified in order to possess greater expression capabilies. 
The modifications are typically replacement of a virus-encoded open reading frame, not 
essential for genome replication, with the gene of interest such that the minimal-virus systems 
lack the ability to systemically infect a host. Examples of each system will be provided in the 
following sections with Figure 1 illustrating the genetic structures of independent and minimal 
virus systems derived from the tobacco mosaic tobamovirus. (TMV) genome. 
4.1. Independent-virus vectors 
Initial RNA virus vectors were functionally minimal-virus vectors that utilized a “gene 
replacement” strategy where a foreign gene of interest replaced the capsid protein (CP) gene 
of a virus [11]. These early vectors expressed foreign genes, but, as with other minimal-virus 
systems, lacked certain virus functions thereby limiting activities. For example, brome 
mosaic virus (BMV) CP replacement vectors could not even move from cell to cell in an 
infected leaf [11], and although TMV-based CP replacement vectors could move from cell to 
cell, they could not move systemically in inoculated plants [35-37].  
With greater understanding of virus function, plant RNA virus vectors were constructed to 
express a foreign gene product in addition to all required viral proteins [36, 38]. These 
vectors were the first independent-virus system that expressed recombinant products while 
moving systemically in a host plant. To construct independent-virus systems for (+) strand 
RNA viruses, vectors exploit subgenomic mRNA production to express foreign genes by 
using an additional subgenomic promoter inserted into the virus [38-40]. For viruses that 
used polyprotein processing, the foreign gene was inserted in translational frame with the 
existing virus open reading frame (ORF) and peptide sequences that facilitate the proteolytic 
processing of the fusion protein were present to insure release of the recombinant protein. 
Some independent-virus vectors are designed to express potential products as fusions to 
viral proteins, such as the potatovirus X (PVX) CP (reviewed in [41]). Often the fusion 
methodology employs the foot and mouth virus 2A translational cleavage sequence (see 
references in [42]). The apparent pausing of the ribosome, and the discontinuity of the 
peptide bond that results, allows proteins upstream and downstream of the 2A sequence to 
be differentially targeted, such as a single chain antibody accumulating in the plant apoplast 
while the CP was sequestered in its normal cytosolic localization [43]. Using these strategies, 
independent-virus systems have been derived from the genomes of potexviruses (including 
potato virus X; PVX), tobamoviruses (including TMV), comoviruses (including cowpea mosaic 
virus), potyviruses, tobraviruses, closteroviruses and others [12, 13, 15]. 
Most independent-virus vectors are functional in Nicotiana or other herbacious species. This 
follows from their ease of inoculation and the receptivity of species to virus expression 
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systems. Recently, the adaptation of closterovirus vectors to a non-herbacious plant system 
was accomplished by adaption of Grapevine leafroll-associated virus-2 into an expression 
vector [44]. This vector showed characteristic phloem-associated expression in inoculated 
grapevines involving the roots, stems, petioles, leaves and berries. A grapevine-A vector 
was also shown to induce inhibitory RNA (RNAi) of model genes in micropropogated 
grapevines [45]. These vectors for use in expression and RNAi-based functional genomics 
studies open new non-transgenic strategies for researchers in woody plants. 
As a more detailed example of an independent-virus system, Tobamoviruses-based vectors 
have been commonly used for recombinant protein expression. These viruses have a (+) 
sense single stranded RNA genome of ~6400 nucleotides helically encapsidated by many 
~2,100 copies of a 17.5 kDa CP in rigid rod shaped particles [12]. The viral 
replication-associated proteins are directly transcribed from the genomic RNA directly, 
whereas expression of internal genes is through the production of subgenomic RNAs. 
Sequences in the tobamovirus genome function as subgenomic promoters regulating the 
production of subgenomic RNAs. The virus movement protein MP and CP are translated 
from two separate, but co-terminal, subgenomic RNAs, with the CP being among the most 
abundant protein and RNA produced in the infected cell [46]. In a tobamovirus infected plant 
there are several milligrams of CP produced per gram of infected tissue. 
Tobamoviruses-based vectors are readily constructed as independent-virus systems, 
including cell-to-cell and systemic movement activities mediated by MP and CP, 
respectively (Figure 1). These vectors benefit from the strength of the viral subgenomic 
promoter’s activity to reprogram the translational activities of infected plant cells such that 
virus-encoded proteins are synthesized at high levels, often similar to the TMV CP [40]. A 
foreign gene encoding the protein for overexpression is added in place of the virus CP so it 
will be expressed from the endogenous virus CP promoter [38, 40]. A second CP promoter 
from a different tobamoviruses strain, of sequence divergent to the first CP promotor, is 
placed downstream of the heterologous coding region and a virus CP gene is then added 3’ 
terminal to the heterologous subgenomic promoter. Tobamoviruses-based vectors infect 
various species, but most commonly tobacco-related species (genus Nicotiana), including 
tabacum and benthamiana. For the vector to express foreign proteins, the infectious vector 
RNA enters plant cells via wounds induced by an abrasive. The virus RNA is released from 
the CP subunits, translated to produce replication-associated proteins and is replicated in 
the initial cell. The progeny RNA is moved to adjacent cells in association with the MP to 
produce infection foci. A proportion of the RNA, complexed with CP, enters the plants 
vascular system for transport to phloem sink tissues in the aerial leaves. This movement 
produces the systematic infection and the foreign gene is expressed in all cells that express 
other virus protein products. Within the cell, the foreign protein is deposited in the site 
dictated by its protein sequence, either naturally or purposely engineered [12, 46]. 
Tobamoviruses-based vectors have been used by literally hundreds of researchers to produce 
a range of human enzymes, antimicrobials, cytokines, subunit vaccine and immunoglobulin 
proteins. Several reviews have provided surveys of these products [12, 14]. In general, 
expression results were obtained in Nicotiana hosts and proteins were extracted from leaf 
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tissues using total homogenization and clarification methods or leaf infiltration and isolation 
of interstitial fluids [46, 47]. Several products have been purified using differential 
separation and standard chromatographic separations and tested in various model systems 
of human disease. TMV-based vectors, especially the well-developed GENEWARE® system, 
have been used to express a large range of recombinant proteins under research and Current 
Good Manufacturing Practice (cGMP) compliance [14].  One class of products has been 
successfully tested in human clinical trials, as described below. 
Active vaccination of Non-Hodgkin’s Lymphoma (NHL) patients with cancer antigens, in 
this case the idiotypic antibody expressed by the tumorogenic B-cells, has been shown to 
induce clinical remissions in human clinical trials [48]. However, more efficient and effective 
vaccines are sought. Full antibodies contain both idiotype-specific elements as well as 
constant sequences, shared by many antibodies, which may reduce the immunogenicity of 
the vaccine. In order to provide higher antigen content to vaccines, single chain antibodies 
(scFvs) were constructed from tumor-derived idiotypic antibodies to provide simpler and 
more sequence-focused vaccines for clinical testing. This vaccine strategy was shown to be 
effective in murine models of NHL [49] and a GENEWARE®-based production methodology 
was developed that could produce >80% of scFvs from human tumor samples [50]. Sixteen 
patients were enrolled in a Phase I clinical trial under the regulatory oversight of the US 
Food and Drug Administration [31, 51]. Vaccines were successfully produced for all patients 
and applied in two dosing groups with and without granulocyte-macrophage 
colony-stimulating factor adjuvant. The primary endpoint of the study was safety which, as 
the first parenteral administration of a plant-made vaccine, was an important outcome to 
monitor. The study results confirmed the safety of plant-derived vaccines, including 
plant-specific glycoforms present on 15 of the 16 vaccines. The secondary endpoint was 
determination of the immunogenicity of the vaccines in human subjects. Overall, 70% of the 
patients developed cellular or humoral immune responses to the scFv vaccines, with the 
adjuvant improving the frequency of responses, as predicted. The majority of the responses 
was shown to be vaccine specific and did not cross react with control idiotype proteins. 
These results demonstrated the flexibility of the TMV-based expression systems as well as 
the safety and effectiveness of the plant derived products [31, 51]. 
4.2. Minimal-virus vectors 
In contrast to independent-virus vectors, minimal-virus systems are capable of functions 
supporting RNA replication, yet are lacking in one or more functions necessary for systemic 
infection. Although this vector was the first type constructed, researchers moved away from 
this approach in favor of the independent-virus vectors. However, as limitations emerged 
from independent-virus systems, including the size of genes that can be expressed, host 
range limitations and problems with systemic movement, researchers revised minimal-virus 
systems with new energy. The resulting vectors were found to be incapable of systemic 
movement in inoculated plants, thus they must be delivered to each and every plant leaf to 
allow cell-to-cell movement activities allow infection of all inoculated leaves. Standard 
abrasion methods are too tedious to deliver inoculum to each leaf, so new methods were 
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developed. The most common method is Agro-infiltration of host plants to launch the 
infection process [33, 52-54]. This process introduces a DNA plasmid, containing the virus 
vector under the control of an appropriate transcriptional unit within normal Ti plasmid 
integration sites, into Agrobacterium tumefaciens cells to create an inoculum. The 
Agrobacterium strain containing the DNA expression constructs are grown in overnight 
cultures and diluted for inoculation. Plants are inverted, submerged in inoculum solution 
and a vacuum is applied removing the air trapped in the leaves. As the vacuum is released, 
the inoculum replaces the air in the leaf spaces providing the Agrobacterium strain access to 
cells throughout the submerged leaves for invasion. The bacteria then exploits the transfer 
DNA mechanisms to introduce the DNA copy of the virus expression vector into the 
nucleus of infected plants. RNA transcription produces infectious RNA or mRNA 
transcripts that are processed by nuclear enzymes into an intact and capped transcript and 
exported to the cytoplasm. These transcripts are then translated and replication protein 
expression initiates similar to independent-virus systems. 
The activity of viral movement proteins move the vectors from the initially infected cells to 
adjacent cells creating a more rapid and synchronous infection of inoculated leaves than 
independent-virus vectors. This eliminates the delays associated with systemic plant 
movement and can yield greater amounts of recombinant proteins in a shorter period of 
time than independent-virus systems [33, 54]. This approach increases the genetic load 
carried by the minimal-virus systems allowing efficient expression of larger recombinant 
proteins [55]. Minimal-virus systems have been developed from the genomes of potexviruses, 
tobamoviruses, bromoviruses, comoviruses and geminiviruses [12, 13]. 
Nicotiana benthamiana is an ideal host for minimal-virus expression since it highly susceptible 
to Agrobacterium infection to mediate initial entry and introduction of the viral expression 
vectors. The expression of a defective form of RNA dependent RNA polymerase in N. 
benthamiana [56] makes it nearly universally susceptible to plant viruses and the great 
experience with this host has led it to be the common host for independent-virus as well for 
the expression of many recombinant proteins. The flexibility of Agroinfiltration inoculation 
procedures allow more than one expression vector into a host plant in a given treatment. 
The co expression of silencing suppressor proteins has been shown to be a key factor for 
optimized yields [57-59]. Such methods have been used to produce a range of 
biopharmaceutical proteins [60-62] and offer strategies to modify the plant enzymatic 
machinery, producing more stable and “human” like recombinant proteins, including 
glycan structures [34, 60] which will be discussed later in this review. 
Examples of minimum-virus vectors include the systems developed using TMV genomes 
include those developed by (Figure 1)[63,64]. Two TMV variants were developed – one, 
actually an independent-virus system, employed the full TMV virus capable of systemic 
movement [63] and a second – lacked the virus coat protein as minimum-virus system [64]. 
The minimum-virus system (TRBO vector) produced significantly higher levels of the green 
fluorescent protein (up to 5.5 mg/g FW). This vector did not require the co-expression of a 
silencing suppressor and worked with very high inoculum dilution in infiltration medium. 
The RNA2 of cowpea mosaic virus (CPMV) was also adapted as a minimum-virus system 
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which overcame the historic limitation of the insert size in CPMV vectors and allows 
expression hetero-oligomeric proteins from a single vector [65, 66]. However, the system 
also requires co-expression of silencing suppressors for optimal expression. 
DNA viruses have been adapted to minimal virus systems. Both single and bipartite plant 
geminivirus systems have modified to produce recombinant proteins – usually at the 
expense of expression of the capsid or key movement or transmission proteins. Maize streak 
virus is an example of a single component virus which has been converted into an 
expression vector [67]. Bean yellow dwarf virus (BeYDV) has been developed into a single 
and dual-component replicon system that permits simultaneous, efficient replication of two 
DNA replicons and thus high-level accumulation of one or two recombinant proteins in the 
same plant cell [68, 69]. This system has been used to produce express immunoglobulin 
proteins and human papilloma virus HPV-16 and the p24 protein of HIV-1 [70]. The system 
requires co-expression of the silencing suppressors. Some geminivirus systems have been 
adapted to express recombinant proteins in non-Nicotiana species, including lettuce [71]. 
The most advanced minimum-virus system is magnICON®. This technology has been used 
to express a large number of recombinant proteins, including cytokines, interferon, bacterial 
and viral antigens, growth hormone, single chain antibodies (reviewed in [54, 72]). The 
ability of Agroinfiltration to introduce more than one expression vector into a host plant in 
the same inoculation allows the use of two magnICON® vectors to produce heteromeric 
recombinant proteins, such as mAbs. For production of mAbs, two non-competitive virus 
vectors are used: one based on turnip vein clearing tobamovirus (TVCV) and the second, 
potatovirus X (PVX [55, 73]). In mAb production, two magnICON® virus expression vectors 
each contain a separate mAb chain, heavy or light, and are co-delivered by Agroinfiltration. 
Each vector replicates independently and expresses mAb chains in the same cells that 
self-assemble functional mAbs at yields up to 1 g/kg fresh weight [33, 54, 55]. These vectors 
have been used for efficient large scale production of multi-gram batches of mAbs under 
Current Good Manufacturing Practices that have been tested in several challenge model 
systems, including non-human primates [14, 74]. 
5. Synergy of transgenic plants and virus-based expression vectors 
Standard integrative plant expression vectors allow transformation of plant lines using 
Agrobacterium tumefaciens-mediated transfer-DNA delivery methods. These methods allows 
for great flexibility and synergy when mixed with transient, virus-based expression vectors. 
The mixture of these two approaches allows for the efficient expression of the recombinant 
biopharmaceutical protein of interest and provision of the required co-factors improving 
pharmaceutical protein yield and processing. As noted above, the co-expression of silencing 
suppressor proteins has been shown to be a key factor for optimized yields with some 
minimal-virus expression systems. Further, entire protein processing systems can be 
introduced into plants to produce more stable and “human” like recombinant proteins, 
including glycan structures [60, 34]. Concerns over the potential immunogenicity of 
plant-specific glycan linkages on recombinant proteins (the presence of β1,2-xylosylation 
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and core α1,3-fucosylation) have been mitigated by the use of RNAi technologies to 
down-regulate endogenous beta1,2-xylosyltransferase and alpha1,3-fucosyltransferase 
genes [75-77] in N. benthamiana plant lines. Proteins produced from these lines show almost 
homogeneous N-glycan species without detectable beta 1,2-xylose and alpha1,3-fucose 
residues providing a host that produces humanized glycan structures. Indeed, production of 
antibody products using the magICON® system using the RNAi plants have demonstrated 
the synergy of the systems – rapid production of high quantity production of antibodies that 
show humanized glycan structures [14]. Indeed, the lack of fucose glycans on mAb products 
produced in the N. benthamiana producing humanized glycans have shown enhanced 
potency in the treatment of Ebola infection in a non-human primate model, anti-tumoral 
investigations of a plant-derived trastuzumab in murine xenograph models and HIV-1 
neutralization studies [74, 78, 79]. The mechanism responsible for this enhanced in vivo 
activity appears to be the improved Fcγ and FcγRIII receptors of nonfucosylated, plant 
produced mAbs. This advantage based on glycan engineering offers great promise for plant 
derived biosimilar antibody products. 
The present of sialic acid terminal sugars on glycan structures of human plasma proteins is 
correlated with their long half-life and the pharmacokinetic properties of effective 
recombinant therapeutics which must function in human plasma [80]. The capability to 
sialylate plant proteins has been demonstrated in transient and transgenic Arabidopsis 
systems by [81-83]. This effort required transformation events providing enzymatic 
synthesis of the sialic acid metabolic precursor, which is normally not synthesized in plants, 
in addition to transferase activities. Efforts are now ongoing to introduce this multi-genic 
modification into N. benthamiana. This glyco-modified host in combination with transient 
virus-based expression of recombinant proteins benefiting from sialylation offers potential 
single-step production of human plasma enzymes with similar pharmacokinetic properties 
as the native proteins. By eliminating any need for post-production enzyme modification, 
successful development and deployment of these plant lines would contribute to both faster 
speed of delivery and lower cost of goods. From these examples, the synergy between 
tailored expression hosts, genetically engineered for appropriate protein post-translational 
modifications, and virus-based expression strategies to provide recombinant products that 
meet the biological function and production rigors of modern biotechnology. 
6. Transient virus-based expression: Transitioning from dicot- to 
monocotyledonous plants 
The focus of the previous material was virus expression systems providing recombinant 
protein expression primarily in plant dicotyledonous plant species. This emphasis comes 
from the historical emphasis on dicot expression due to the availability of more facile 
systems. Yet monocotyledonous species, especially the cereals, are the most important of 
crops for feeding humans and livestock in many parts of the world. Further, maize, 
sugarcane, bamboo and other monocot species, are used extensively in the production of 
biofuels and other industrial products. Monocots possess unique morphological features 
and seed biology suggesting gene functions not present in dicots. Monocot species have also 
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developed unique mechanisms for tolerance of adverse environmental conditions like 
drought and high salinity. In the past, most protein functions were proposed based on 
homology to better characterized dicot systems, such as Arabidopsis thaliana, but functional 
assays are required to truly ascertain gene function. Overexpression and RNAi gene 
silencing strategies are key to these direct studies [84]. The construction of transgenic plant 
lines is not an adequate solution due to the time consuming nature of the approach and the 
frequency of lethal phenotypes. Therefore, a more rapid, transient strategy is needed. RNA 
virus expression vectors offer such powerful tools for understanding the biology of these 
species. In the remaining sections of this review, we will examine the contributions that 
monocot viral expression systems have made and provide a few detailed examples. 
6.1. Use of transient expression vectors as functional gene discovery tools in 
moncot species 
One of the challenges in developing any plant based expression system is to achieve high 
level expression without triggering the post translational gene silencing (PTGS) and related 
RNAi mechanisms that plants and other organisms have evolved (reviewed in [18]). These 
mechanisms have been observed to operate in transgenic plants, and even exploited to 
generate pathogen-derived resistance to viruses in cases where the silencing of viral 
transgenes prevents related viruses from infecting the transgenic host [85, 86]. The 
identification of plant viral proteins that are able to suppress these silencing mechanisms 
suggested that these mechanisms have evolved in part to prevent or slow viral infection. 
Expression of proteins using viral vectors can also trigger PTGS, and is referred to as viral 
induced gene silencing (VIGS). Using VIGS, an endogenous plant gene can be silenced by 
inserting only a small portion of the target gene (100-500 nt in length) which creates loss of 
function phenotypes to study gene function. A wide range of viruses have been developed 
as VIGS vectors, originally, and most extensively, for dicot hosts [18, 87]. Shortly after the 
first dicot examples, a barley stripe mosaic virus (BSMV) vector, was used to silence the 
endogenous phytoene desaturase (pds) gene systemically in barley [88]. 
BSMV, the type member of the hordeivirus family, infects many agriculturally important 
monocot species such as barley, rice, corn, oat and wheat [89-92]. It is known to be highly 
seed transmitted in barley, which could be a potential advantage for assessing gene function 
in seeds and early development. As showen in Figure 2, BSMV has a tripartite (+) sense 
RNA genome consisting of RNAs  and  [93]. The virus uses well characterized 
subgenomic promoters for gene expression from each of its genomic RNAs [94]. 
As a more detailed example of a VIGS vector, BSMV was constructed by inserting fragments of 
the silencing target so that they would be expressed only as untranslated RNA on a 
subgenomic promoter following the b ORF [88]. Although the strongest silencing in barley 
plants was observed using the barley pds fragments, fragments from pds taken from maize and 
rice caused a degree of silencing that was proportional to their sequence similarity with the 
barley homolog. Further modification of the virus to delete the coat protein enhanced the 
suppression of the endogenous pds. Since this first demonstration of VIGS in barley, BSMV 
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silencing vectors have been successfully used to demonstrate gene functions related to 
pathogen resistance, aphid defense, development and mophogenesis in a variety of monocots 
including oat, rice, and the model grass Brachypodium distachyon [87]. BSMV mediated VIGS 
was recently shown to operate in root, leaf and meiotic tissues of wheat, along with efforts to 
optimize its efficacy in this important agricultural host [95]. In addition, BSMV mediated VIGS 
can be inherited and has been observed for up to 6 generations in wheat and barley, which not 
only enhances the range of phenotypes that can be explored for reasons related to the timing of 
developmental events, but also because progeny frequently have fewer viral symptoms [87, 
96]. Most recently, the  RNA has been modified to incorporate untranslated foreign gene 
fragments and was used with the modified  RNA vector described above to silence two 
endogenous genes simultaneously, or to achieve enhanced silencing of a single gene [97]. In 
addition to BSMV, a strain of BMV has also been engineered as a VIGS vector and has been 
used successfully in barley, rice and maize [98, 99]. 
 
Figure 2. The general structure of BSMV genomic RNAs  and . Boxes represent the open reading 
frames on each RNA and are labeled with the the viral protein they encode. Arrows indicate the 
position of subgenomic promoters used to express the downstream proteins. 
Coupling VIGS with high-throughput cloning and sequencing technologies has additionally 
allowed these viral vectors to be used in functional genomics. In this approach, cDNA 
libraries are constructed within virus expression vectors and gene function to be assessed by 
screening infected plant hosts for phenotypic or metabolic changes measured by various 
input and output focused screening assays. TMV and PVX VIGS vectors were the first to 
employed in this manner in the dicot N. benthamiana, with BSMV used shortly after in the 
monocot barley [84, 100]. Since these first reports, vector systems for functional genomics 
have continued to be refined and optimized in an expanding number of hosts [18, 87], 
including systems amenable for high throughput screens in monocots based on BSMV [101, 
102]. 
6.2. Use of transient virus expression systems for recombinant protein 
expression in monocot species 
As with dicot expression vectors, monocot vectors include both minimal and independent 
virus vectors [103]. As noted above, minimal type BMV vectors have been constructed by 
replacing the coat protein ORF with a foreign gene. For example, French et al. [11] used this 
strategy to express the CAT protein in barley protoplasts. In another example, involving 
BSMV, substitution of the open reading frame (ORF) for the βb triple gene block 1 (TGB1) 
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movement protein was used to express the luciferase reporter gene [104]. An example of an 
independent vector is one based on the potyvirus, wheat streak mosaic virus (WSMV). In 
this system the foreign ORF is inserted in frame within the virus polyprotein and flanked by 
cleavage sequences that allow for its release after translation [105]. These systems have the 
limitations of low foreign gene insertion efficiency and the smaller number of hosts that can 
be infected and tested for recombinant protein expression. 
6.3. Using barley stripe mosaic virus vectors for recombinant protein expression 
BSMV has been developed to express recombinant proteins as fusions to several individual 
virus proteins expressed from subgenomic RNAs. To date these systemic vectors have not 
incorporated any sequences to liberate the foreign protein from the fusion protein. For 
example Lawrence and Jackson [106] expressed GFP as a fusion to the N terminus of the βb 
(TGB1) protein at levels sufficient to explore the function of the viral protein in cell-to-cell 
movement. Higher levels of expression however were achieved with fusions to the C-
terminus of the BSMV b protein. This includes systemic expression of a b::GFP fusion 
protein used to study viral movement in barley [107, 108]. More recently, C-terminal b 
fusions have been use to test the fungal ToxA protein activity in wheat, barley and N. 
benthamiana [109]. In the latter case, the recombinant virus genome, containing the ToxA 
gene, was sufficiently stable that Agroinfiltrated N. benthamiana was used as the inoculum 
source for systemic expression in barley and wheat. ToxA phenotypes were replicated in all 
species. The systemic expression by BSMV of non-fusion recombinant proteins in barley and 
wheat has been achieved by substituting most of the b ORF with the gene for either the 
wild type and mutant ToxA protein [110]. Again, the resulting phenotypes indicate the 
ToxA proteins were expressed appropriately. 
These efforts to develop independent viral expression vectors in monocots are extended by 
previously unpublished work described here. Our aim in this work was to improve foreign 
gene stability, increase the level of foreign gene expression, and generate free, non-fusion, 
foreign proteins that could function and localize independently of viral proteins. 
Expression of GFP::b Fusion Protein from RNA  
To test whether insert stability was related to the fusion orientation, we constructed a vector 
with GFP fused (indicated by the “::” in construct name) to N-terminus of the b protein 
(.GFP::b, Figure 3A). Co-inoculation of protoplasts and barley leaves with and RNAs 
(BSMV-GFP::b) resulted GFP fluorescence and fusion protein accumulation to levels that 
were indistinguishable from co-inoculations with ,  and b::GFP (BSMV-b::GFP) as 
shown in Table 1 (compare #3 and #4). However, as the infection in plants progressed 
beyond 7 dpi, GFP fluorescence and fusion protein accumulation were observed longer in 
.GFP::b infected plants than in those infected with .b::GFP. Specifically, GFP::b 
expression is regularly observed in leaves 1-4 above the inoculated leaf by BSMV-GFP::b, 
compared to 1-2 leaves for BSMV-b::GFP (data not shown). Thus, the GFP gene is generally 
maintained and expressed by BSMV-GFP::b to 18 dpi. We believe that the increased 
stability of fusions to the N-terminus of b results from more restrictive requirements for the 
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deletion of the GFP gene in order to gain a competitive advantage. For example, internal 
deletions in the GFP ORF have a one in three chance of maintaining the continuity of the 
ORF with b, which is critical because b is an important virulence factor for BSMV [111]. 
Thus, those deletions which result in a b frame shift are likely to be less competitive than 
those viruses which maintained the full GFP ORF. In contrast, for C-terminal fusions of GFP 
to b, all deletions within the GFP ORF would maintain b expression and would 
presumably be more competitive than the parental virus due the reduced genetic load. 
 
Figure 3. Genomic organization of BSMV  RNAs engineered to express GFP. Vector components 
.b::GFP and .GFP::b as designed to produce a fusion of GFP to the b protein C and N terminus, 
respectively (a). The vector component a.b-GFP designed to produce only free GFP (b). Vector 
components .b::2A-GFP and .GFP::2A-b as designed to produce a free GFP protein following 
cleavage by the FMDV 2A cleavage sequence from the b protein C or N terminus, respectively (c). 
Open boxes indicate ORFs, hatched boxes indicate untranslated ORF sequences, grey boxes indicate 
FMDV 2A cleavage sequence, arrows indicate subgenomic promoters. EcoRV restriction sites indicate 
the position of the a sequences that have been deleted from the wild type  RNA. 
Inoculum GFP expression Systemic symptoms of 
BSMV infection 




Plants Barley Plants 
1   none  - - yes 
2   TMV-GFP ***** - no 
3   .b::GFP **** systemic yes 
4   .GFP::b  **** systemic yes 
5   .a.b.GFP - - no 
6   .a.b.GFP  ***** - yes 
Table 1. Comparative expression of GFP in tobacco protoplasts and barley plants using BSMV vector 
constructs 
Expression of native GFP from RNA  
To develop a BSMV vector able to express a free foreign protein, we tested a variety of novel 
vectors with the most promising of which described here. In each case, the BSMV  RNA 
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was modified to express GFP in combination with wild type BSMV  and  RNA. A three 
component vector with RNA , , and a.b-GFP (a RNA containing a deletion of a, 
the replicase protein ORF, and GFP in place of the b ORF, Figure 3C) did not express GFP 
in protoplasts (#5, Table 1). However, the addition of wild type  RNA created a four 
component vector, which was equivalent in GFP expression levels to TMV 30B (TMV-GFP 
[40]) in protoplasts (compare #6 with #2, Table 1). In contrast to its behavior in protoplasts, 
the four component vector did not express GFP systemically in barley, even though 
systemic viral symptoms were observed (#6, Table 1), apparently due to the loss of the GFP 
bearing component during systemic movement. This system may be amenable to expression 
in whole plants if delivered using an Agroinoculation strategy, or in transgenic plants 
expressing the a and b proteins to complement RNA , , and a.b-GFP. 
In a different approach, BSMV vectors expressing N- and C-terminus fusions of GFP to 
BSMV b were modified to release GFP in vivo after autocleavage of the fusion protein. 
Cleavage of the fusion protein was achieved by inserting the foot and mouth disease virus 
(FMDV) 2A co-translational cleavage sequence [112, 113] between the fused ORFs 
(Figure 3C). Western analysis of GFP::2A::b and b::2A::GFP infected tobacco protoplasts 
and barley plants revealed that the FMDV 2A cleavage sequence was at least >90% effective 
in both cases (data not shown). Viral spread and GFP fluorescence in barley plants infected 
with GFP::2A::b was indistinguishable from those containing GFP::b. In contrast, the 
systemic spread of the BSMV-b::2A::GFP virus was slightly delayed compared to BSMV-
b::GFP (data not shown). Both BSMV-b::2A::GFP and BSMV-GFP::2A::b were able to 
infect and express GFP in N. benthamiana plants in a manner similar to that reported for 
b::GFP [108].  
 
Figure 4. BSMV Coat protein deletion vector and GFP expression. Genomic organization of BSMV  
RNA engineered with a deletion of the BSMV coat protein, a (a). Open boxes indicate ORFs, hatched 
boxes indicate indicate untranslated ORF sequences, arrows indicate subgenomic promoters. BstB1 
restriction site indicates the position of the a sequences that have been deleted from the wild type  
RNA. Western blot analysis of b::GFP protein in barley leaves (b). 
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  (c) 
 
Figure 5. Genomic organization of BSMV  RNAs and expression of free GFP or heterologous proteins 
from a cDNA library. Vector components .GFP::HA::2A-b and .cDNA::HA::2A-b as designed to 
produce a fusion of GFP or a heterologous protein with an HA epitope tag and the FMDV 2A sequence. 
The 2A sequence is designed to release the b protein is during translation (a). Open boxes indicate 
ORFs, checkered boxes indicate the HA epitope sequence, grey boxes indicate FMDV 2A cleavage 
sequence, arrows indicate subgenomic promoters. Western blot analysis of GFP::HA fusion protein in 
barley leaves (b). Graph of rice cDNA sequences arranged according to size (c). cDNAs whose predicted 
proteins were detected by Western blot analysis are unshaded, while blue shaded bars indicate the lack 
of detectable HA tagged protein. Green bar represents the internal GFP::HA::2A control. 
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Coat Protein Deletion Enhances Expression from b Subgenomic Promoter 
The coat protein (a) of BSMV is not required for systemic infection. To determine the 
impact of a deletion on b subgenomic expression, a  genomic RNA containing a deletion 
of the a ORF was constructed (.a, Figure 4A). In tobacco protoplasts, using a 
increased GFP accumulation from the  RNA 2-5 fold for viruses bearing the b fusions 
(b::GFP, GFP::b, b::2A::GFP, and GFP::2A::b) or GFP substitutions of b 
(a.b.GFP) (Figure 4B and data not shown). Using .a also increased GFP 
fluorescence and accumulation for b::GFP, GFP::b, b::2A::GFP, and GFP::2A::b, in 
systemic barley tissue (data not shown). 
Expression of Epitope Tagged Heterologous Proteins from RNA  Derived Vectors 
To detect heterologous proteins, .GFP::2A-b was modified to contain the hemagglutinin 
(HA) epitope tag fused between GFP and the FMDV 2A cleavage sequence (.GFP::HA::2A-
b, Figure 4A). In barley plants infected with BSMV RNAs a,and.and 
.GFP::HA::2A-b, Western blot analysis detected the HA tagged GFP (Figure 5B). The 
addition of the HA tag had no effect on the efficiency of the 2A cleavage sequence. These 
results suggested that the HA epitope tags would allow for the efficient detection of BSMV 
expressed heterologous proteins. 
To test the flexibility of BSMV to express heterologous proteins in barley, plant genes, from 
a variety of subcellular locations were expressed as N-terminal fusions to HA::2A-b 
(.cDNA::HA::2A-b, Figure 5A). A total of 42 full-length rice genes were amplified from 
sequenced, cDNA library clones and inserted in frame with the HA::2A-b ORF. All 42 
.cDNA::HA::2A-b RNAs were infectious when co-inoculated onto barley plant with BSMV 
RNAs  and a. For each vector, systemically infected barley tissue was tested in 
replicate for recombinant protein expression using two anti-HA antibodies. From the 42 
genes, 38 genes showed confirmed expression of protein product in each plant tested 
(Figure 5C). In each case, the size of the protein detected in the Western blot was consistent 
with the size predicted for the post-cleavage heterologous protein, with the addition of the 
HA epitope tag and the 2A sequence. The 2A cleavage differed between the different 
heterologous genes, but cleavage rates of 60-95% were usually observed. 
In our survey of 42 full length rice ORFs between 200 and 1800 nucleotides in size. The 
resulting gene products including proteins of 38, 46, 54 and 64 kDa proteins. Due to the 
average insert size of the library, proteins of 20-30 kDa were most commonly detected in our 
study. The flexibility of the BSMV expression vector was further demonstrated is ability to 
successfully express proteins of cytosolic localization (GFP and BMV CP) and those that are 
matured through the plant secretory pathway (including a lysozyme, interferon, human 
growth hormone and protease inhibitor). The maturation of these proteins demonstrates the 
ability of the 2A cleavage system to deliver proteins to distinct subcellular fates and still 
retain activity. In addition, these data also demonstrate the ability of the vector to express 
genes from both plant and animal sources successfully. 
In summary, to develop a monocot vector capable of expressing free, heterologous proteins, 
we have tested a variety of strategies based on the BSMV RNA. All of the strategies relied 
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on expression from the b subgenomic RNA facilitating expression of >90% (38/42) 
recombinant proteins tested. The recombinant proteins were of a variety of sizes, ranging 
from 11 to 64 kDa. These data demonstrate that monocot recombinant expression vectors 
can be developed that show many of the flexile and attractive features of traditional dicot 
expression systems. These vectors can be deployed for testing the function of plant genes in 
both monocot and dicot species as well as express proteins of recombinant proteins of 
biomedical importance. 
 
Dicot Vectors Monocot Vectors
Primarily monopartite genomes with some 
multipartite examples 
Primarily multipartite genomes with a 
monopartite example 
Independent and minimal-virus vectors 
demonstrated for whole plant expression 
Independent-virus vectors only demonstrated 
for whole plant expression; minimal-virus 
vectors restricted to cell culture expression 
Vector delivery as infectious RNA transcripts or 
Agroinfiltration of DNA-based expression 
vectors 
Vector delivery as infectious RNA transcripts 
Successfully used for gene silencing and gene 
overexpression 
Successfully used for gene silencing and gene 
overexpression 
Systemic expression of foreign proteins 
primarily through non-genetic fusion strategies 
Systemic expression of foreign proteins 
primarily through genetic fusions to virus 
proteins and inclusion of cleavage sequences 
Expression of single gene cistrons Potential expression of multiple cistrons as and 
 gene fusions 
Systemic expression of wide range of gene sizes 
and classes of proteins 
Systemic expression of wide range of gene sizes 
and classes of proteins 
Successful integration into cGMP recombinant 
protein production environment 
Not integrated to date into cGMP production 
environment 
Table 2. Comparison of properties of virus vectors for expression in dicot and monocotyledonous plant 
species.  
7. Conclusion 
The last few decades have seen tremendous progress in developing tools and expertise to 
produce recombinant proteins in plants. Although conceptually straightforward, the 
technical hurdles included not only improving our understanding of plant biology, 
development of expression systems, but also the perfection of purification and analytical 
methods to meet the specifications of research, industrial and medical applications. The 
successes described in this chapter involved a convergence of economic incentives, market 
forces and regulatory acceptance, the latter being particularly important for biomedical 
products. Throughout much of this time, transient viral expression systems have played a 
significant role. The adaptability of virus systems and their ease of use continue to help push 
the boundaries of recombinant protein expression in plants. Beginning with a few examples, 
highlighted in this review, a diverse array of viral vector systems have emerged capable of 
delivering target genes to a wide array of host species, and compliant with a wide range of 
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regulatory and technical constraints. As shown in this chapter, expression successes initially 
observed in dicotyledonous plants have now been extended to monocotyledonous plants 
through the use of the BSMV genome. A comparison of the properties of virus vectors 
designed for recombinant protein expression in dicot and monocot plant species is provided 
in Table 2. Research continues to improve their effectiveness and ease of use. Indeed, the 
advantages of low development costs, flexible design, and relatively quick turnaround from 
conception to proof of principle to scale up, will continue to drive innovation and 
application of viral expression vectors. The synergy of customizing specific plant hosts for 
post-translational modifications offers a strategy to produce plant-sourced products which 
match the needs of the proposed end uses. Further, the unexpected discovery of viral 
vectors as tools to silence specific genes in plants has also been of tremendous value to the 
plant research community, and has effectively complemented their use in overexpression in 
a way that has only begun to be appreciated and applied in the last decade. The use of these 
two complementary approaches to address functional genomics in a high throughput 
fashion, and on a broad range of hosts, will likely emerge in the coming years. 
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